179 related articles for article (PubMed ID: 35842520)
1. Factors affecting inter-individual variability in endoxifen concentrations in patients with breast cancer: results from the prospective TOTAM trial.
Braal CL; Westenberg JD; Buijs SM; Abrams S; Mulder TAM; van Schaik RHN; Koolen SLW; Jager A; Mathijssen RHJ
Breast Cancer Res Treat; 2022 Aug; 195(1):65-74. PubMed ID: 35842520
[TBL] [Abstract][Full Text] [Related]
2. Toward model-informed precision dosing for tamoxifen: A population-pharmacokinetic model with a continuous CYP2D6 activity scale.
Agema BC; Buijs SM; Sassen SDT; Mürdter TE; Schwab M; Koch BCP; Jager A; van Schaik RHN; Mathijssen RHJ; Koolen SLW
Biomed Pharmacother; 2023 Apr; 160():114369. PubMed ID: 36753957
[TBL] [Abstract][Full Text] [Related]
3. Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.
Klopp-Schulze L; Joerger M; Wicha SG; Ter Heine R; Csajka C; Parra-Guillen ZP; Kloft C
Clin Pharmacokinet; 2018 Feb; 57(2):229-242. PubMed ID: 28540639
[TBL] [Abstract][Full Text] [Related]
4. CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy.
Teft WA; Gong IY; Dingle B; Potvin K; Younus J; Vandenberg TA; Brackstone M; Perera FE; Choi YH; Zou G; Legan RM; Tirona RG; Kim RB
Breast Cancer Res Treat; 2013 May; 139(1):95-105. PubMed ID: 23580071
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.
Hertz DL; Deal A; Ibrahim JG; Walko CM; Weck KE; Anderson S; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Graham M; Peppercorn JM; Jones DR; Desta Z; Flockhart DA; Evans JP; McLeod HL; Carey LA; Irvin WJ
Oncologist; 2016 Jul; 21(7):795-803. PubMed ID: 27226358
[TBL] [Abstract][Full Text] [Related]
6. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
Dezentjé VO; Opdam FL; Gelderblom H; Hartigh den J; Van der Straaten T; Vree R; Maartense E; Smorenburg CH; Putter H; Dieudonné AS; Neven P; Van de Velde CJ; Nortier JW; Guchelaar HJ
Breast Cancer Res Treat; 2015 Oct; 153(3):583-90. PubMed ID: 26369533
[TBL] [Abstract][Full Text] [Related]
7. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
Borges S; Desta Z; Li L; Skaar TC; Ward BA; Nguyen A; Jin Y; Storniolo AM; Nikoloff DM; Wu L; Hillman G; Hayes DF; Stearns V; Flockhart DA
Clin Pharmacol Ther; 2006 Jul; 80(1):61-74. PubMed ID: 16815318
[TBL] [Abstract][Full Text] [Related]
8. Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.
Hennig EE; Piatkowska M; Karczmarski J; Goryca K; Brewczynska E; Jazwiec R; Kluska A; Omiotek R; Paziewska A; Dadlez M; Ostrowski J
BMC Cancer; 2015 Aug; 15():570. PubMed ID: 26232141
[TBL] [Abstract][Full Text] [Related]
9. Cross-Ancestry Genome-Wide Association Study Defines the Extended CYP2D6 Locus as the Principal Genetic Determinant of Endoxifen Plasma Concentrations.
Khor CC; Winter S; Sutiman N; Mürdter TE; Chen S; Lim JSL; Li Z; Li J; Sim KS; Ganchev B; Eccles D; Eccles B; Tapper W; Zgheib NK; Tfayli A; Ng RCH; Yap YS; Lim E; Wong M; Wong NS; Ang PCS; Dent R; Tremmel R; Klein K; Schaeffeler E; Zhou Y; Lauschke VM; Eichelbaum M; Schwab M; Brauch HB; Chowbay B; Schroth W
Clin Pharmacol Ther; 2023 Mar; 113(3):712-723. PubMed ID: 36629403
[TBL] [Abstract][Full Text] [Related]
10. Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen.
Klopp-Schulze L; Mueller-Schoell A; Neven P; Koolen SLW; Mathijssen RHJ; Joerger M; Kloft C
Front Pharmacol; 2020; 11():283. PubMed ID: 32296331
[TBL] [Abstract][Full Text] [Related]
11. Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study.
Fox P; Balleine RL; Lee C; Gao B; Balakrishnar B; Menzies AM; Yeap SH; Ali SS; Gebski V; Provan P; Coulter S; Liddle C; Hui R; Kefford R; Lynch J; Wong M; Wilcken N; Gurney H
Clin Cancer Res; 2016 Jul; 22(13):3164-71. PubMed ID: 26847054
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.
Sanchez-Spitman A; Dezentjé V; Swen J; Moes DJAR; Böhringer S; Batman E; van Druten E; Smorenburg C; van Bochove A; Zeillemaker A; Jongen L; Los M; Neven P; Gelderblom H; Guchelaar HJ
J Clin Oncol; 2019 Mar; 37(8):636-646. PubMed ID: 30676859
[TBL] [Abstract][Full Text] [Related]
13. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.
de Graan AJ; Teunissen SF; de Vos FY; Loos WJ; van Schaik RH; de Jongh FE; de Vos AI; van Alphen RJ; van der Holt B; Verweij J; Seynaeve C; Beijnen JH; Mathijssen RH
J Clin Oncol; 2011 Aug; 29(24):3240-6. PubMed ID: 21768449
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen.
ter Heine R; Binkhorst L; de Graan AJ; de Bruijn P; Beijnen JH; Mathijssen RH; Huitema AD
Br J Clin Pharmacol; 2014 Sep; 78(3):572-86. PubMed ID: 24697814
[TBL] [Abstract][Full Text] [Related]
15. Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score.
Wu AH; Lorizio W; Tchu S; Lynch K; Gerona R; Ji W; Ruan W; Ruddy KJ; Desantis SD; Burstein HJ; Ziv E
Breast Cancer Res Treat; 2012 Jun; 133(2):677-83. PubMed ID: 22294487
[TBL] [Abstract][Full Text] [Related]
16. The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels.
Opdam FL; Dezentje VO; den Hartigh J; Modak AS; Vree R; Batman E; Smorenburg CH; Nortier JW; Gelderblom H; Guchelaar HJ
Cancer Chemother Pharmacol; 2013 Mar; 71(3):593-601. PubMed ID: 23228987
[TBL] [Abstract][Full Text] [Related]
17. Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping.
Binkhorst L; Mathijssen RH; Jager A; van Gelder T
Cancer Treat Rev; 2015 Mar; 41(3):289-99. PubMed ID: 25618289
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen.
Sanchez-Spitman AB; Swen JJ; Dezentje VO; Moes DJAR; Gelderblom H; Guchelaar HJ
Expert Rev Clin Pharmacol; 2019 Jun; 12(6):523-536. PubMed ID: 31008668
[No Abstract] [Full Text] [Related]
19. Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype.
Martinez de Dueñas E; Ochoa Aranda E; Blancas Lopez-Barajas I; Ferrer Magdalena T; Bandrés Moya F; Chicharro García LM; Gómez Capilla JA; Zafra Ceres M; de Haro T; Romero Llorens R; Ferrer Albiach C; Ferriols Lisart R; Chover Lara D; López Rodríguez A; Munárriz Ferrandis J; Olmos Antón S
Breast; 2014 Aug; 23(4):400-6. PubMed ID: 24685597
[TBL] [Abstract][Full Text] [Related]
20.
Tamura K; Imamura CK; Takano T; Saji S; Yamanaka T; Yonemori K; Takahashi M; Tsurutani J; Nishimura R; Sato K; Kitani A; Ueno NT; Mushiroda T; Kubo M; Fujiwara Y; Tanigawara Y
J Clin Oncol; 2020 Feb; 38(6):558-566. PubMed ID: 31821071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
